Chris Klomp, a senior federal health official, spoke at a STAT event Thursday and offered a reality check about President Trump’s drug discount platform TrumpRx.
Despite President Trump speaking in grand terms about the platform, calling it “transformative” and promising “the biggest prescription drug price reductions in history,” Klomp offered a more measured perspective on stage at STAT’s Breakthrough Summit East event in New York. He said the program was not intended to be used by the majority of Americans with health insurance, and rejected suggestions that President Trump’s drug policies amount to price caps.
“The goal wasn’t really mass reach,” Klomp said, adding, “170 million Americans have commercial insurance, 68 million Americans have Medicare, and the rest rely primarily on Medicaid and CHIP. TrumpRx is not for most of them, it’s a cash benefit.”
STAT+ exclusive story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article and get in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
Individual plan Group plan See all plans
To read the rest of this story, subscribe to STAT+.
Subscribe
Source link
